SuperGen (SUPG) Stock Price, News & Analysis

Company Overview

Astex Pharmaceuticals, Inc., formerly SuperGen, Inc. is a pharmaceutical company. The Company is primarily engaged in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. The Company is developing a pipeline of medicines for partnership with pharmaceutical companies. It is also engaged in the application of fragment-based drug discovery and development of small-molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, Astex Therapeutics Limited, a wholly owned subsidiary, has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. In October 2013, Otsuka Holdings Co Ltd announced that its wholly owned subsidiary, Otsuka Pharmaceutical Co., Ltd completed, through its wholly owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SUPG Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of SuperGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SuperGen investors own include Bristol-Myers Squibb (BMY), Arbutus Biopharma (ABUS), Abiomed (ABMD), ARCA biopharma (ABIO), AbbVie (ABBV), American Assets Trust (AAT).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SUPG
• CIK: 919722
• Web: astx.com
• Phone: +1-925-5600100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A